Quantification of the benefit of earlier thrombolytic therapy: five-year results of the Grampian Region Early Anistreplase Trial (GREAT).
暂无分享,去创建一个
[1] W. Weaver,et al. Time to thrombolytic treatment: factors affecting delay and their influence on outcome. , 1995, Journal of the American College of Cardiology.
[2] Barr Jb,et al. HOME OR AWAY? , 1964, Lancet.
[3] J. Herlitz,et al. Components of delay time in suspected acute myocardial infarction with particular emphasis on patient delay , 1990, Journal of internal medicine.
[4] J. Rawles. Problems in quantifying the benefit of earlier thrombolysis in acute myocardial infarction , 1995 .
[5] E. Gang,et al. Decreased incidence of ventricular late potentials after successful thrombolytic therapy for acute myocardial infarction. , 1989, The New England journal of medicine.
[6] Johan Herlitz,et al. Indications for fibrinolytic therapy in suspected acute myocardial infarction : collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994 .
[7] A. Davie. Early thrombolytic treatment in acute myocardial infarction , 1996, The Lancet.
[8] Gusto Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. , 1993, The New England journal of medicine.
[9] E. Rose,et al. Delay between the onset of symptoms of acute myocardial infarction and seeking medical assistance is influenced by left ventricular function at presentation. , 1995, British heart journal.
[10] J. Rawles. Halving of mortality at 1 year by domiciliary thrombolysis in the Grampian Region Early Anistreplase Trial (GREAT). , 1994, Journal of the American College of Cardiology.
[11] T. Waterston. FLUIDS FOR DIARRHŒA IN YOUNG CHILDREN , 1977, The Lancet.
[12] D. Bonaduce,et al. Effects of late administration of tissue-type plasminogen activator on left ventricular remodeling and function after myocardial infarction. , 1990, Journal of the American College of Cardiology.
[13] A. M. Skene,et al. TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION Anglo-Scandinavian Study of Early Thrombolysis (ASSET) , 1988, The Lancet.
[14] R. Collins,et al. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. , 1997, The New England journal of medicine.
[15] C. Fry,et al. Science of urinary incontinence Report of a Meeting of Physicians and Scientists, University College London , 1994, The Lancet.
[16] M. Simoons,et al. Letter to the Editor. Effect of thrombolytic treatment delay on myocardial infarct size , 1992 .
[17] J. Bourke,et al. Reduction in incidence of inducible ventricular tachycardia after myocardial infarction by treatment with streptokinase during infarct evolution. , 1990, Journal of the American College of Cardiology.
[18] Feasibility, safety, and efficacy of domiciliary thrombolysis by general practitioners: Grampian region early anistreplase trial. GREAT Group. , 1992, BMJ.
[19] P. Kudenchuk,et al. Prehospital-initiated vs hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial. , 1993, JAMA.
[20] Eric Boersma,et al. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour , 1996, The Lancet.
[21] J. Rawles,et al. Magnitude of benefit from earlier thrombolytic treatment in acute myocardial infarction: new evidence from Grampian region early anistreplase trial (GREAT) , 1996, BMJ.
[22] R. Schröder,et al. Prehospital thrombolysis: beneficial effects of very early treatment on infarct size and left ventricular function. , 1993, Journal of the American College of Cardiology.
[23] S. Schmidt,et al. The prehospital phase of acute myocardial infarction in the era of thrombolysis. , 1990, The American journal of cardiology.
[24] P. Marino,et al. Effect of streptokinase on left ventricular modeling and function after myocardial infarction: the GISSI (Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico) Trial. , 1989, Journal of the American College of Cardiology.
[25] R. Madhok,et al. Duration of anticoagulation for deep-vein thrombosis and pulmonary embolism , 1992, The Lancet.
[26] F. Sheehan,et al. Time from onset of symptoms to thrombolytic therapy: A major determinant of myocardial salvage in patients with acute transmural infarction , 1987 .
[27] J. Perry. Prehospital-initiated vs hospital-initiated thrombolytic therapy for myocardial infarction. , 1994, JAMA.
[28] J. Rawles,et al. Impact of resuscitation and thrombolysis on mortality rate from acute myocardial infarction. , 1995, International journal of cardiology.
[29] Aims Trial Study Group. EFFECT OF INTRAVENOUS APSAC ON MORTALITY AFTER ACUTE MYOCARDIAL INFARCTION: PRELIMINARY REPORT OF A PLACEBO-CONTROLLED CLINICAL TRIAL , 1988, The Lancet.
[30] M. Simoons,et al. Effect of thrombolytic treatment delay on myocardial infarct size , 1992, The Lancet.
[31] J. Ritchie,et al. Early versus late hospital arrival for acute myocardial infarction in the western Washington thrombolytic therapy trials. , 1989, The American journal of cardiology.
[32] The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. , 1993, The New England journal of medicine.
[33] M. Hori,et al. Late Reperfusion for Acute Myocardial Infarction Limits the Dilatation of Left Ventricle Without the Reduction of Infarct Size , 1993, Circulation.
[34] Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. , 1993, The New England journal of medicine.